Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-2103 (Xyotax) + Capecitabine in Metastatic Breast Cancer
NCT00265733Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2006
- Primary completion
- Aug 2007
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel poliglumex in breast cancer, sponsored by Cancer and Leukemia Group B. Primary endpoint: Proportion of confirmed tumor response (complete and partial response) up to 5 years. Started Feb 2006; status: completed.
02
Drugs
paclitaxel poliglumex
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00265733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265733.